Perspectives in antisense therapeutics

Pharmacology & Therapeutics
S Agrawal, R P Iyer

Abstract

Modulation of gene expression using oligonucleotides (oligos) is currently an area of intense activity, both from therapeutic, as well as research perspectives. To develop oligos as therapeutic agents, in addition to demonstrable biological activity, in vivo metabolic stability, tissue disposition and pharmacokinetics are important considerations. Oligodeoxynucleoside phosphorothioates are the first-generation antisense analogs that have been studied extensively, and are in clinical trials against a number of disease indications. In an effort to improve the antisense properties of these compounds, mixed-backbone oligos incorporating different chemical modifications have been synthesized and evaluated for antisense activity. The present review will provide an overview of the pharmacokinetics and toxicology following intravenous, intraperitoneal, subcutaneous and oral administration of mixed-backbone oligos as second-generation antisense therapeutics.

References

Jan 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·P C Zamecnik, M L Stephenson
Jun 21, 1990·Biochimica Et Biophysica Acta·C Hélène, J J Toulmé
Sep 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalJ Y Tang
Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·P S SarinP C Zamecnik
Jan 1, 1995·Clinical Pharmacokinetics·S AgrawalJ Tang
Jan 1, 1995·Journal of Clinical Laboratory Analysis·S K Srinivasan, P Iversen
Feb 1, 1995·Current Opinion in Biotechnology·S Agrawal, R P Iyer
Dec 1, 1995·Toxicology Letters·S AgrawalD R Shaw
May 14, 1996·Proceedings of the National Academy of Sciences of the United States of America·R OberbauerT W Meyer
Oct 1, 1996·Trends in Biotechnology·S Agrawal
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalR Zhang

❮ Previous
Next ❯

Citations

Oct 5, 2010·Cancer Chemotherapy and Pharmacology·Eckhardt S FerdinandiAiping H Young
Jun 9, 2005·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Gabor LendvaiAnne Roivainen
Sep 29, 2000·Pharmacology & Therapeutics·C Garcia-ChaumontJ Bolard
Apr 18, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·F WuB Långström
Jan 5, 1999·Bioorganic & Medicinal Chemistry Letters·D A SarracinoC Richert
Jan 5, 1999·Bioorganic & Medicinal Chemistry Letters·G TosquellasJ L Imbach
May 18, 1999·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·S S GambhirM E Phelps
Mar 17, 2007·Nucleosides, Nucleotides & Nucleic Acids·R Krishna KumarVasulinga T Ravikumar
Apr 7, 1999·Journal of Hematotherapy·C M Verfaillie
Jul 12, 2001·Antisense & Nucleic Acid Drug Development·T D SamaniA Laigle
Sep 27, 2001·Antisense & Nucleic Acid Drug Development·I KhanN Thomas
Jan 25, 2000·Antisense & Nucleic Acid Drug Development·S H KangR Kole
May 11, 2000·Antisense & Nucleic Acid Drug Development·S NakajimaM Hashida
Mar 22, 2000·Antisense & Nucleic Acid Drug Development·O KhatsenkoR S Geary
Jul 20, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher S GondiJasti S Rao
May 11, 2012·Cancer Investigation·Robert J AmatoRobert E Martell
Apr 11, 2015·Pharmacology & Therapeutics·Ke LiuJinrong Min
Feb 6, 2009·Biotechnology Progress·Maggie LawP Chen
Dec 19, 2003·Expert Opinion on Biological Therapy·P J WhiteC J Wraight
May 16, 2000·The Journal of Gene Medicine·V BudkerJ A Wolff
Apr 30, 2002·Clinical Pharmacokinetics·Richard S GearyLisa R Grillone
Dec 31, 2018·Molecular Therapy. Nucleic Acids·Bao T LeRakesh N Veedu
Nov 10, 2000·Methods : a Companion to Methods in Enzymology·N Toschi
Feb 15, 2008·Clinical Genitourinary Cancer·Robert J Amato
Feb 27, 2008·Journal of the American Chemical Society·Agnes NoyModesto Orozco
Mar 31, 2005·Journal of the American Chemical Society·Agnes NoyModesto Orozco

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

Current Opinion in Molecular Therapeutics
Kelly L WarfieldSina Bavari
Ciba Foundation Symposium
S Agrawal, R Zhang
Current Cancer Drug Targets
S Agrawal, Ekambar R Kandimalla
Proceedings of the National Academy of Sciences of the United States of America
S AgrawalR Zhang
Current Opinion in Molecular Therapeutics
Ekambar R KandimallaS Agrawal
© 2022 Meta ULC. All rights reserved